Published in Biol Blood Marrow Transplant on May 01, 2008
TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol (2010) 1.97
Efficacy of itraconazole prophylaxis for autologous stem cell transplantation in children with high-risk solid tumors: a prospective double-blind randomized study. Yonsei Med J (2011) 0.75
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med (2007) 24.19
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet (2011) 12.13
Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst (2011) 4.52
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol (2007) 4.40
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 4.24
Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 4.07
PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res (2009) 3.95
Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol (2009) 3.53
Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol (2013) 3.31
miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell (2010) 3.27
Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J Clin Oncol (2011) 3.22
Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Eur Urol (2012) 3.20
Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. J Clin Oncol (2008) 3.16
Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ. J Clin Oncol (2010) 2.97
BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood (2012) 2.91
Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med (2007) 2.90
Chromosomal translocations induced at specified loci in human stem cells. Proc Natl Acad Sci U S A (2009) 2.73
Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol (2006) 2.70
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2009) 2.54
Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol (2009) 2.50
HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res (2011) 2.43
A PP4-phosphatase complex dephosphorylates gamma-H2AX generated during DNA replication. Mol Cell (2008) 2.28
Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin Cancer Res (2013) 2.26
The influence of margin width and volume of disease near margin on benefit of radiation therapy for women with DCIS treated with breast-conserving therapy. Ann Surg (2010) 2.26
Carboplatin for stage I seminoma and the sword of Damocles. J Clin Oncol (2005) 2.25
Sunitinib does not accelerate tumor growth in patients with metastatic renal cell carcinoma. Cell Rep (2013) 2.24
Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer. J Clin Oncol (2007) 2.20
A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood (2013) 2.14
Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer (2011) 2.13
Inactivation of murine Usp1 results in genomic instability and a Fanconi anemia phenotype. Dev Cell (2009) 2.12
Medical treatment of advanced testicular cancer. JAMA (2008) 2.11
Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. N Engl J Med (2003) 2.09
Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin Cancer Res (2013) 2.09
Carboplatin in clinical stage I seminoma: too much and too little at the same time. J Clin Oncol (2011) 2.07
Chemotherapy for teratoma with malignant transformation. J Clin Oncol (2003) 2.06
TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol (2010) 1.97
Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol (2004) 1.95
Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo differentiation of human male germ cell tumors. Cancer Res (2006) 1.94
Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol (2007) 1.90
Axillary dissection can be avoided in the majority of clinically node-negative patients undergoing breast-conserving therapy. Ann Surg Oncol (2013) 1.84
The p400 ATPase regulates nucleosome stability and chromatin ubiquitination during DNA repair. J Cell Biol (2010) 1.80
Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients. Cancer (2006) 1.79
Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. J Clin Oncol (2008) 1.78
Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst (2010) 1.76
Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma. J Clin Oncol (2007) 1.74
Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin Cancer Res (2006) 1.72
Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy. J Clin Oncol (2005) 1.71
Phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol (2010) 1.70
Endorectal MR imaging before salvage prostatectomy: tumor localization and staging. Radiology (2006) 1.69
Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol (2005) 1.68
Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med (2010) 1.66
Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J Exp Med (2012) 1.65
Sequelae of treatment in long-term survivors of testis cancer. Eur Urol (2011) 1.64
A single-institution validation of the AJCC staging system for stage IV melanoma. Ann Surg Oncol (2008) 1.64
Clinical outcome and predictors of survival in late relapse of germ cell tumor. J Clin Oncol (2008) 1.63
Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion. J Urol (2005) 1.62
Radiation injury after a nuclear detonation: medical consequences and the need for scarce resources allocation. Disaster Med Public Health Prep (2011) 1.60
Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol (2004) 1.58
Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy. Clin Cancer Res (2014) 1.57
Systematic classification and prediction of complications after nephrectomy in patients with metastatic renal cell carcinoma (RCC). BJU Int (2012) 1.57
Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer. Cancer (2011) 1.56
Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin Genitourin Cancer (2009) 1.56
Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist (2008) 1.55
Hypoxia-inducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: possible therapeutic implications. BJU Int (2010) 1.54
Occult malignancy in patients undergoing contralateral prophylactic mastectomy. Ann Surg (2011) 1.53
Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour. BJU Int (2007) 1.51
Immunohistochemical expression of hypoxia inducible factor-1alpha and its downstream molecules in sarcomatoid renal cell carcinoma. J Urol (2007) 1.51
Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer (2006) 1.51
Late relapse of testicular germ cell tumors. Urol Oncol (2005) 1.50
Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. Eur Urol (2012) 1.50
Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer. Clin Cancer Res (2012) 1.50
A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Invest New Drugs (2006) 1.46
Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer (2011) 1.45
Comparative patient-centered outcomes (health state and adverse sexual symptoms) between adjuvant brachytherapy versus no adjuvant brachytherapy in early stage endometrial cancer. Ann Surg Oncol (2014) 1.45
Double-blind, placebo-controlled, randomized trial of granulocyte-colony stimulating factor during postoperative radiotherapy for squamous head and neck cancer. Cancer J (2006) 1.42
An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma. J Natl Cancer Inst (2013) 1.42
Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. J Clin Oncol (2005) 1.41